daihai30
2021-05-20

The picture shows: The signing ceremony of strategic cooperation between Genetron Health and JD HEALTH was held ceremoniously. The leading guests from left to right are:

Zhang Zhenlong, General Manager of JD HEALTH Medical Insurance Medical Development Department, Xiao Jianbo, General Manager of JD HEALTH Internet Medical Department, Liu Mingyan, General Manager of JD HEALTH Healthy City, Wang Dongyuan, General Manager of JD HEALTH Smart Medical Department, Wang Yufang, General Manager of JD HEALTH Consumer Medical Department, Xin Lijun, Senior Vice President of JD.com Group and CEO of JD HEALTH, Wang Sizhen, Co-founder and CEO of Genetron Health, Lei Li, Senior Vice President of Genetron Health, Xu Ce, Chief Financial Officer of Genetron Health, Teng Lin, Vice President of Genetron Health, Zhang Fengling, Vice President of Genetron Health, and Fu Tianchen, Senior Director of Strategic Products of Genetron Health Early Screening Division

The cooperation between the two sides is driven by online and offline engines, focusing on six core contents: consumer medicine, Internet liver disease management, government medical association, mutual sharing of screening customer resources, industry and user education, and tumor center resource construction. The first round of cooperation between the two sides will focus on liver cancer and lung cancer. Genetron Health relies on HCCScreenTM, a liquid biopsy product for early screening of liver cancer, and the combined detection kit for human 8 gene mutation, and cooperates with JD HEALTH to cover early screening of cancer, molecular typing, medication guidance and drug resistance monitoring, so as to provide more accurate, efficient and accessible cancer full-cycle management services for a wider range of users.The picture shows: The signing ceremony of strategic cooperation between Genetron Health and JD HEALTH was held ceremoniously. The leading guests from left to right are:

Zhang Zhenlong, General Manager of JD HEALTH Medical Insurance Medical Development Department, Xiao Jianbo, General Manager of JD HEALTH Internet Medical Department, Liu Mingyan, General Manager of JD HEALTH Healthy City, Wang Dongyuan, General Manager of JD HEALTH Smart Medical Department, Wang Yufang, General Manager of JD HEALTH Consumer Medical Department, Xin Lijun, Senior Vice President of JD.com Group and CEO of JD HEALTH, Wang Sizhen, Co-founder and CEO of Genetron Health, Lei Li, Senior Vice President of Genetron Health, Xu Ce, Chief Financial Officer of Genetron Health, Teng Lin, Vice President of Genetron Health, Zhang Fengling, Vice President of Genetron Health, and Fu Tianchen, Senior Director of Strategic Products of Genetron Health Early Screening Division

The cooperation between the two sides is driven by online and offline engines, focusing on six core contents: consumer medicine, Internet liver disease management, government medical association, mutual sharing of screening customer resources, industry and user education, and tumor center resource construction. The first round of cooperation between the two sides will focus on liver cancer and lung cancer. Genetron Health relies on HCCScreenTM, a liquid biopsy product for early screening of liver cancer, and the combined detection kit for human 8 gene mutation, and cooperates with JD HEALTH to cover early screening of cancer, molecular typing, medication guidance and drug resistance monitoring, so as to provide more accurate, efficient and accessible cancer full-cycle management services for a wider range of users.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment